SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Booker T. Washington — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBooker T. Washington
Date of birth1856-04-05
IdentifiersMRN HR-NI017-SYN-TD; SSN (made up) 000-17-2284
Document date1915-06-29
AuthorLorraine Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week check after adding chlorthalidone. [S]

History of Present Illness

Mr. Washington returns four weeks after chlorthalidone was added. His home readings run in the 120s and low 130s over 70s and 80s. He has had no headaches for six weeks, and his concentration is a little better. He has had no lightheadedness on standing, muscle cramps, or joint pain, and he takes all five medicines every morning from a weekly organizer. He still gets up once or twice a night to urinate. [S]

ElementDetail
Home blood pressure120s to low 130s over 70s to 80s
SymptomsNo headaches for six weeks; concentration a little better
Medication toleranceNo lightheadedness, cramps, or joint pain on chlorthalidone
AdherenceWeekly organizer; every dose taken

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; weight stable
CardiovascularNegativeNo chest pain, palpitations, or ankle swelling
MusculoskeletalNegativeNo cramps or joint pain
GenitourinaryPositiveUp once or twice a night to urinate; no dysuria
NeurologicalNegativeNo headache or lightheadedness on standing

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04activeS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04 to 1915-05-11completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-11activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-11activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route1915-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1915-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1915-06-29Body height170cmS
1915-06-29Body weight70kgS
1915-06-29Body mass index (BMI) [Ratio]24.2kg/m2S
1915-06-29Systolic blood pressure128mm[Hg]S
1915-06-29Diastolic blood pressure80mm[Hg]S
1915-06-29Heart rate74/minS
1915-06-29Respiratory rate14/minS
1915-06-29Body temperature36.7CelS
1915-06-29Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1915-06-29Sodium [Moles/volume] in Serum or Plasma135mmol/L135-145 mmol/LNormalS
1915-06-29Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1915-06-29Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
1915-06-29Urea nitrogen [Mass/volume] in Serum or Plasma36mg/dL6-24 mg/dLHighS
1915-06-29Creatinine [Mass/volume] in Serum or Plasma2.4mg/dL0.74-1.35 mg/dLHighS
1915-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M30mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1915-06-29Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1915-06-29Albumin/Creatinine [Mass Ratio] in Urine360mg/g<=30 mg/gHighS

Physical Exam

Vital signs recorded on 1915-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Blood pressure128/80 mmHg, the average of two seated readings after five minutes' rest; no fall on standing
HeartRegular rhythm, rate 74; soft S4
LungsClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150activeconfirmed I12.9S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R.
Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosisactiveconfirmed N18.32S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease.
Hypertensive retinopathy, both eyes, without papilledemaactiveconfirmed H35.033S — Synthetic funduscopic finding that echoes the documented failing vision.
Mild anemia of chronic kidney disease, iron replete; monitoractiveconfirmed D63.1S — Synthetic finding from the baseline hemoglobin and iron studies.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPotassium and creatinine (basic metabolic panel)2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR drawCompleted todayFour weeks after starting chlorthalidone. Potassium 4.3, sodium 135 (low-normal), creatinine 2.4 mg/dL, eGFR 30: stable
LaboratoryUrine albumin-creatinine ratioAbout 3 times a year for G3b A3Completed today360 mg/g, down 56 percent from 820; still A3
LaboratoryeGFR and urine albumin, next pairAbout 3 times a year for G3b A3DueNext at the six-month review, in about four months
LaboratoryCalcium, phosphate, and PTHEvery 6 to 12 months in G3bDueAt the six-month review
Laboratory25-hydroxyvitamin DOnce at baselineDuePlanned with the six-month calcium, phosphate, and PTH
LaboratoryHemoglobinAt least yearly in G3DueAt the six-month review
SurveyKidney failure risk equation, 2 and 5 yearsYearly in G3 to G5DueAt the six-month review
LaboratoryLipid panelOnce at diagnosis in chronic kidney disease; 4 to 12 weeks after a statin start in the lipid monographNot indicatedLDL 138 mg/dL at diagnosis. The CKD monograph and KDIGO advise against routine follow-up LDL testing once a statin is started, and the care plan follows them; this departs by choice from the lipid monograph's 4 to 12 week panel, whose window is now open
ExaminationStandardized office blood pressureEvery visit; target systolic below 120 when toleratedCompleted today128/80 mmHg; below 130/80 but above the systolic target of 120
ExaminationWeight, BMI, and cardiac auscultationEvery visitCompleted today70 kg; soft S4
Medication safetyChlorthalidone safetyEach visit while startingCompleted todaySodium 135 and potassium 4.3; no orthostatic fall, cramps, or gout
Medication safetyMedication review: NSAID avoidance and kidney dosingEvery visitCompleted todayNo NSAIDs; doses checked for eGFR 30
Medication safetyVaccination reviewYearly in chronic kidney diseaseCompleted todayHepatitis B vaccine dose 2 today; influenza vaccine due in the fall
Self-managementHome blood pressure log, sodium below 2 g a day, and activityEvery visitCompleted todayHome log reviewed; walking most days

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)

Follow-up: Preventive visit in September. Six-month blood pressure and kidney review with eGFR, urine albumin, hemoglobin, calcium, phosphate, PTH, vitamin D, and the kidney failure risk. Next scheduled visit 1915-09-21: periodic adult preventive visit. [S]